Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹111 Cr
verified against source
Revenue YoY
23%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 crore (up 23% YoY), EBITDA up 73%, and PAT up 74%. Growth was driven by D2C product expansion, higher ticket sizes (now ₹3,250), and the ramp-up of a new 30-bed hospital in Delhi. Management guided for product revenue of ₹300 crore in FY27 and ₹500 crore in FY28, supported by subsidiary Ajuni Life Sciences, US operations, and AI-driven efficiency gains. A strategic partnership with Gina aims to add 300 beds by FY27 and 1,000 by FY28, with a blended PAT margin target of 18-20% by H1 FY28. Key risk: hospital occupancy ramp-up may be slower than expected, given current utilization below 10% and pending insurance empanelment.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects product revenue to reach ₹300 crore in FY27, driven by 25% organic growth, subsidiary ramp-up, and US operations.
- Management targets ₹500 crore product revenue in FY28, supported by ticket size expansion and new product launches.
- Management expects PAT margin to improve from 8.5% to 11-12% in FY27 due to operating leverage.
- Management plans to have 300 beds operational by Q4 FY27, with 150-200 beds in collaboration with Gina.
Risks flagged
- Current hospital occupancy is below 10% and break-even is not yet achieved; slower-than-expected ramp-up could delay profitability.
- RBI approval for the US subsidiary is pending, which could delay equity infusion and operational scaling.
- Advertisement spend remains at 40% of revenue, limiting margin expansion; management expects only gradual reduction to 38%.
- Hospital business requires significant working capital (50% of bed cost), and cash generation has been weak in FY26.
Key quotes
- We were a product company categorized as a product company. We will definitely remain as a product company primarily but yes we are moving into a full-fledged ecosystem into the complete sphere of the healthcare of Ayurveda.
- Our few test results are very positive and we as since inception Satkatar always looks into the ROI. So AI has started giving ROI and improving our efficiency into the company.
- I would instead of 100% I would recognize 15% but try to understand that this 15% would have not been with me for the next two years.
Research modules